Cargando…

An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system

The active compounds present in Hypericum perforatum L. (Hypericaceae) include hyperforin, hypericins and flavonoids, which are assumed to be responsible for the activity of the extract in the treatment of wounds and scars. The present study aimed to incorporate H. perforatum extract standardized to...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Mohamed, Abdel Motaal, Amira, Ahmed, Mohammed A., Alsayari, Abdulrhman, El-Gazayerly, Omaima N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058565/
https://www.ncbi.nlm.nih.gov/pubmed/29382233
http://dx.doi.org/10.1080/10717544.2018.1431977
_version_ 1783341724058255360
author Ali, Mohamed
Abdel Motaal, Amira
Ahmed, Mohammed A.
Alsayari, Abdulrhman
El-Gazayerly, Omaima N.
author_facet Ali, Mohamed
Abdel Motaal, Amira
Ahmed, Mohammed A.
Alsayari, Abdulrhman
El-Gazayerly, Omaima N.
author_sort Ali, Mohamed
collection PubMed
description The active compounds present in Hypericum perforatum L. (Hypericaceae) include hyperforin, hypericins and flavonoids, which are assumed to be responsible for the activity of the extract in the treatment of wounds and scars. The present study aimed to incorporate H. perforatum extract standardized to a known content of phloroglucinols, naphthodianthrones and polyphenolic compounds into an effective transdermal drug delivery system capable of entrapping both lipophilic and hydrophilic constituents in the form of niosomal gels for wound treatment. An 80% ethanol extract (HE) was prepared on a pilot scale using DIG-MAZ. An HPLC-DAD holistic profile was established for HE and was standardized to contain 3.4 ± 4 rutin, 1.1 ± 3 chlorogenic acid, 0.5 ± 2 quercitrin, 2.8 ± 2 hyperforin, and 0.51 ± 3% w/w total hypericins. Niosomes were prepared using the modified reverse phase evaporation technique (REV). The wound healing effect of the gel was tested on 16 adult mongrel dogs. A significant decrease in the inflammatory cell count (18.4 ± 5.3) was recorded in the niosomal gel 1.5% NaCMC-treated group at the 7th day post wounding. It induced a marked regression in the inflammatory phase and enhanced the early beginning of the proliferative phase of wound healing. After 21 days, it showed complete re-epithelization, formation of new matrix fibers and significant reduction in the wound size, compared to the control and the Panthenol® 2% cream treated groups. This is the first study of H. perforatum in a niosomal topical drug delivery system.
format Online
Article
Text
id pubmed-6058565
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-60585652018-08-17 An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system Ali, Mohamed Abdel Motaal, Amira Ahmed, Mohammed A. Alsayari, Abdulrhman El-Gazayerly, Omaima N. Drug Deliv Research Article The active compounds present in Hypericum perforatum L. (Hypericaceae) include hyperforin, hypericins and flavonoids, which are assumed to be responsible for the activity of the extract in the treatment of wounds and scars. The present study aimed to incorporate H. perforatum extract standardized to a known content of phloroglucinols, naphthodianthrones and polyphenolic compounds into an effective transdermal drug delivery system capable of entrapping both lipophilic and hydrophilic constituents in the form of niosomal gels for wound treatment. An 80% ethanol extract (HE) was prepared on a pilot scale using DIG-MAZ. An HPLC-DAD holistic profile was established for HE and was standardized to contain 3.4 ± 4 rutin, 1.1 ± 3 chlorogenic acid, 0.5 ± 2 quercitrin, 2.8 ± 2 hyperforin, and 0.51 ± 3% w/w total hypericins. Niosomes were prepared using the modified reverse phase evaporation technique (REV). The wound healing effect of the gel was tested on 16 adult mongrel dogs. A significant decrease in the inflammatory cell count (18.4 ± 5.3) was recorded in the niosomal gel 1.5% NaCMC-treated group at the 7th day post wounding. It induced a marked regression in the inflammatory phase and enhanced the early beginning of the proliferative phase of wound healing. After 21 days, it showed complete re-epithelization, formation of new matrix fibers and significant reduction in the wound size, compared to the control and the Panthenol® 2% cream treated groups. This is the first study of H. perforatum in a niosomal topical drug delivery system. Taylor & Francis 2018-01-31 /pmc/articles/PMC6058565/ /pubmed/29382233 http://dx.doi.org/10.1080/10717544.2018.1431977 Text en © 2018 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Ali, Mohamed
Abdel Motaal, Amira
Ahmed, Mohammed A.
Alsayari, Abdulrhman
El-Gazayerly, Omaima N.
An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
title An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
title_full An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
title_fullStr An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
title_full_unstemmed An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
title_short An in vivo study of Hypericum perforatum in a niosomal topical drug delivery system
title_sort in vivo study of hypericum perforatum in a niosomal topical drug delivery system
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058565/
https://www.ncbi.nlm.nih.gov/pubmed/29382233
http://dx.doi.org/10.1080/10717544.2018.1431977
work_keys_str_mv AT alimohamed aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT abdelmotaalamira aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT ahmedmohammeda aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT alsayariabdulrhman aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT elgazayerlyomaiman aninvivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT alimohamed invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT abdelmotaalamira invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT ahmedmohammeda invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT alsayariabdulrhman invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem
AT elgazayerlyomaiman invivostudyofhypericumperforatuminaniosomaltopicaldrugdeliverysystem